Cargando…
Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942
Autores principales: | Zakrzewicz, Anna, Würth, Celina, Beckert, Benedikt, Feldhoff, Simon, Vanderheyden, Katrien, Foss, Stian, Andersen, Jan Terje, de Haard, Hans, Verheesen, Peter, Bobkov, Vladimir, Tikkanen, Ritva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139756/ https://www.ncbi.nlm.nih.gov/pubmed/35626757 http://dx.doi.org/10.3390/cells11101700 |
Ejemplares similares
-
Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
por: Zakrzewicz, Anna, et al.
Publicado: (2022) -
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus
por: Maho-Vaillant, Maud, et al.
Publicado: (2022) -
Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023) -
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
por: Newland, Adrian C., et al.
Publicado: (2019) -
PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
por: Knoebl, P., et al.
Publicado: (2022)